Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $233.00

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its target price upped by Wells Fargo & Company from $207.00 to $233.00 in a research note published on Friday morning, Benzinga reports. The brokerage currently has an equal weight rating on the biopharmaceutical company’s stock.

Other equities research analysts also recently issued reports about the company. Morgan Stanley increased their price target on Alnylam Pharmaceuticals from $250.00 to $255.00 and gave the stock an equal weight rating in a report on Friday, July 12th. Barclays increased their target price on Alnylam Pharmaceuticals from $291.00 to $295.00 and gave the company an overweight rating in a research report on Friday. UBS Group raised their price objective on Alnylam Pharmaceuticals from $253.00 to $288.00 and gave the stock a buy rating in a research report on Friday, June 28th. Bank of America boosted their target price on Alnylam Pharmaceuticals from $248.00 to $295.00 and gave the stock a buy rating in a research note on Tuesday, June 25th. Finally, The Goldman Sachs Group lifted their price target on Alnylam Pharmaceuticals from $174.00 to $198.00 and gave the stock a neutral rating in a research report on Friday. Eight equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of Moderate Buy and a consensus target price of $269.32.

Alnylam Pharmaceuticals Stock Down 2.6 %

NASDAQ ALNY opened at $265.00 on Friday. The firm has a market cap of $33.52 billion, a price-to-earnings ratio of -98.88 and a beta of 0.37. The business has a 50-day moving average price of $211.34 and a 200-day moving average price of $175.01. Alnylam Pharmaceuticals has a twelve month low of $141.98 and a twelve month high of $274.93.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.74) by $0.61. The firm had revenue of $659.83 million for the quarter, compared to the consensus estimate of $447.22 million. During the same period in the previous year, the company posted ($2.21) earnings per share. Alnylam Pharmaceuticals’s quarterly revenue was up 107.0% on a year-over-year basis. Research analysts expect that Alnylam Pharmaceuticals will post -3.99 EPS for the current fiscal year.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, Director David E. I. Pyott sold 32,450 shares of the business’s stock in a transaction that occurred on Monday, June 24th. The stock was sold at an average price of $220.69, for a total transaction of $7,161,390.50. Following the completion of the sale, the director now directly owns 136 shares in the company, valued at approximately $30,013.84. The transaction was disclosed in a document filed with the SEC, which is available through this link. In other news, Director Amy W. Schulman sold 21,700 shares of the company’s stock in a transaction that occurred on Wednesday, May 29th. The stock was sold at an average price of $148.60, for a total value of $3,224,620.00. Following the completion of the sale, the director now directly owns 8,436 shares in the company, valued at $1,253,589.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director David E. I. Pyott sold 32,450 shares of the company’s stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $220.69, for a total value of $7,161,390.50. Following the completion of the sale, the director now owns 136 shares of the company’s stock, valued at $30,013.84. The disclosure for this sale can be found here. In the last three months, insiders sold 89,598 shares of company stock worth $19,377,944. Corporate insiders own 1.50% of the company’s stock.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Large investors have recently made changes to their positions in the stock. ANTIPODES PARTNERS Ltd grew its position in shares of Alnylam Pharmaceuticals by 69.1% in the fourth quarter. ANTIPODES PARTNERS Ltd now owns 189,141 shares of the biopharmaceutical company’s stock valued at $36,203,000 after purchasing an additional 77,307 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Alnylam Pharmaceuticals by 2.5% in the fourth quarter. Vanguard Group Inc. now owns 11,943,895 shares of the biopharmaceutical company’s stock valued at $2,286,181,000 after purchasing an additional 287,064 shares in the last quarter. Robeco Institutional Asset Management B.V. lifted its holdings in Alnylam Pharmaceuticals by 155.7% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 20,549 shares of the biopharmaceutical company’s stock valued at $39,000 after acquiring an additional 12,513 shares during the last quarter. Quattro Financial Advisors LLC lifted its holdings in Alnylam Pharmaceuticals by 2,517.8% in the first quarter. Quattro Financial Advisors LLC now owns 5,000 shares of the biopharmaceutical company’s stock valued at $747,000 after acquiring an additional 4,809 shares during the last quarter. Finally, Westpac Banking Corp lifted its holdings in Alnylam Pharmaceuticals by 59.8% in the fourth quarter. Westpac Banking Corp now owns 1,512 shares of the biopharmaceutical company’s stock valued at $289,000 after acquiring an additional 566 shares during the last quarter. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.